Organisation paid for research Program year 2025 Source: CMS Open Payments

Complete Health Research

Neither a doctor nor a teaching hospital

Research payments

$894,360

140 payments

Through program year 2025, Complete Health Research is reported as receiving $894,360 in research payments, across 140 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $8,233 5
2024 Research $172,709 21
2023 Research $135,099 24
2022 Research $285,396 54
2021 Research $285,144 33
2020 Research $7,778 3

Breakdown

Who paid Research payments · program years 2020–2025
  1. Biohaven Pharmaceutical Holding Company Ltd. $311,326 53 payments
  2. Biohaven Pharmaceuticals, Inc. $213,169 20 payments
  3. AbbVie, Inc. $118,245 36 payments
  4. Pfizer Inc. $111,158 9 payments
  5. Teva Pharmaceuticals USA, Inc. $98,100 9 payments
  6. Amgen Inc. $40,862 12 payments
  7. Galderma Laboratories, L.P. $1,500 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $168,132 22 payments
  2. A Phase 23 Randomized Doubleblind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $155,855 12 payments
  3. BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $153,640 15 payments
  4. A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $120,679 16 payments
  5. A Randomized, Double-Blind, Placebo-Controlled, Parallel- Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Inserts 4 mcg (Teva Pharmaceuticals, Inc.) With IMVEXXY (Estradiol Vaginal Inserts) (TherapeuticsMD, Inc.) in the Treatment of Dyspareunia in Women With Vulvar and Vaginal Atrophy $95,400 8 payments
  6. A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) $61,813 22 payments
  7. A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis $46,006 9 payments
  8. 20170625-Vesalius - CV $25,969 4 payments
  9. A Phase 3 Randomized Doubleblind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents = 6 to <18 Years of Age $19,246 6 payments
  10. Vesalius - CV $7,778 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record